2 results
Approved WMORecruiting
Objectives Primary end point:- to define the MTD of IL-2, subcutaneously given once a day, 5 days per week, for 6 weeks, in combination with a fixed dose of sorafenib in patients with metastatic RCC, clear cell subtype. Secondary end points:- the…
Approved WMORecruiting
The main purpose of this pilot study is to assess the feasibility and potential efficacy of implant retained mandibular advancement device (MAD) therapy on a small scale in edentulous patients with mild to moderate OSA in terms of sleep apnea…